Sascha Berger

Healthcare Investor & Strategic Advisor | Healthtech · Biotech · VC/PE · EMEA | BergerInvest | PhD

📍 Germany🔄 Updated September 2026💼 8 investments📅 9 years investing🗓 Last invested Jan 2026
VC🌍 GermanyInvested this year
8
Total investments
1
Early stage
0
Mid stage
6
Late stage
9y
Years active

Portfolio

8 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Strategic Advisor & Investor
Jan 2026
Founded by Dr Sascha Berger, Berger Invest partners with emerging and growth-stage companies as a strategic advisor and early investor: bridging global innovation with global capital and opportunity.
Board Observer
Feb 2024
Vektor Medical is on a mission to revolutionize arrhythmia care. The FDA-cleared vMap technology, is an AI-based arrhythmia analysis tool, created to improve cardiac ablation outcomes, optimize workflows and increase procedural efficiency.
Board Member & Investor
Dec 2023
myo, a modern communication service for the care sector. With myo, care providers communicate professionally, securely and directly with relatives. Caregivers can document and share content about field trips, medical or organizational updates via text or voice messages, photos and videos. myo allows caregivers more time for the people in their care, and relatives can take part in the daily life of their loved ones. myo is available on any device with internet access. myos service is accessible through our simplified app for iOS and Android users or through myo-web. myo was founded in Germany and has expanded operations to the UK. We are always looking to help care homes give their best quality care and become the bridge that expands residents and relatives social connection. Do drop us a message if you would like to hear more. We are happy to hear from you.
Angel Investor
May 2023
Our patent-pending biotech platform, Phactory, makes designing synthetic proteins 10,000x more effiicent and reduces the material costs by 100x. We are leveraging Phactory to develop the newest classes of protein-based drugs, such as the next generation of antibiotics.
Angel Investor
Mar 2023
Pangea Bio is developing novel therapies that directly activate the TrkB receptor, driving neuronal and synaptic plasticity, and neuroprotection. Dysfunction of the BDNF/TrkB pathway is a hallmark of disorders such as schizophrenia, depression, Alzheimer’s disease, Parkinson’s disease, and glaucoma.
Board Member
Mar 2022
At Egg Medical we believe that all interventional physicians, nurses and techs deserve better protection from scatter radiation in the lab. Egg Medicals EggNest™ Radiation Protection System reduces radiation exposure for everyone in every case by up to 97% without compromising workflow, because #ScatterMatters!
late stageMedical Device
Board Observer
Jan 2020
Leading Technology for the Encapsulation of nucleic acids, biomolecules, and other APIs. Our technology solves your current encapsulation challenges. We offer highly flexible GMP manufacturing solutions for your genetic payloads and other molecules, making manufacturing of transfection material a highly flexible and commercially viable proposition. LEON utilises its’ proprietary nano technology platform for the continuous manufacturing of SMART nanoparticles (ranging from surface stablilised polymeric through to lipid nanoparticles (LNPs) and liposomes). The Company is working with world class industry partners for both process and product development.
Board Observer
Jan 2017
Welcome to our world! All-ceramic restorations date back more than 100 years; around 1900 an American dentist invented the jacket crown. In the 1920s the technique became popular in Europe despite being complicated and tricky to apply. With the advent of CAD/CAM technology in dentistry in the 1980s, the foundation was laid for all-ceramic restorations becoming standard. Today there are a number of different materials available. Zirconium dioxide has shown the greatest potential. At pritidenta everything revolves around this material: this is where our core competence lies, this is our passion. This is all we do - and we do it really well. This is down to internal research and development and manufacturing in-house, which are both done in Germany – and of course a great team. The pritidenta philosophy We develop products for dentists and dental technicians which combine highly aesthetic results with efficient manufacture and automation processes using CAD/CAM. Our aim is to offer our customers a cost-effective.
late stageMedical Device
Experience · 15 entries
All (15)
Investments (8)
Founder (1)
Board (5)
2026
Strategic Advisor & Investor
Jan 2026
Founded by Dr Sascha Berger, Berger Invest partners with emerging and growth-stage companies as a strategic advisor and early investor: bridging global innovation with global capital and opportunity.
2024
Investment Director Biotech
Sep 2024
NEOM is a vision of what the future will be at a time when the world needs innovative solutions. It will be a destination and a home for people who dream big and want to participate in building a new model for sustainable living.  #NEOM
Board Observer
Feb 2024
Vektor Medical is on a mission to revolutionize arrhythmia care. The FDA-cleared vMap technology, is an AI-based arrhythmia analysis tool, created to improve cardiac ablation outcomes, optimize workflows and increase procedural efficiency.
2023
Board Member & Investor
Dec 2023
myo, a modern communication service for the care sector. With myo, care providers communicate professionally, securely and directly with relatives. Caregivers can document and share content about field trips, medical or organizational updates via text or voice messages, photos and videos. myo allows caregivers more time for the people in their care, and relatives can take part in the daily life of their loved ones. myo is available on any device with internet access. myos service is accessible through our simplified app for iOS and Android users or through myo-web. myo was founded in Germany and has expanded operations to the UK. We are always looking to help care homes give their best quality care and become the bridge that expands residents and relatives social connection. Do drop us a message if you would like to hear more. We are happy to hear from you.
Angel Investor
May 2023
Our patent-pending biotech platform, Phactory, makes designing synthetic proteins 10,000x more effiicent and reduces the material costs by 100x. We are leveraging Phactory to develop the newest classes of protein-based drugs, such as the next generation of antibiotics.
Show all 15 entries ↓
Investment activity
2017–2026 · 8 investments
201712020120221202332024120261
Recent (last 2 years)Earlier